Recruiting
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
I8H-MC-BDCL - ClinicalTrials.gov - NCT04450394
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
How long will I be in the trial?
The study will last about 33 weeks and may include up to 21 visits.
Recruiting
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
I8H-MC-BDCL - ClinicalTrials.gov - NCT04450394
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
How long will I be in the trial?
The study will last about 33 weeks and may include up to 21 visits.
Key Requirements
Age :
18-75
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-75
Sex
All
Participants must
Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of a Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor) for at least 3 months prior to screening
Participants must have a HbA1c value of 7.0% to 9.5%, inclusive
Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m²), inclusive
Participants must NOT
Participants must not have type 1 diabetes mellitus or latent autoimmune diabetes
Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)
Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Participants must not have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²
Participants must not have active or untreated cancer
Participants must not be on chronic (>14 days) systemic glucocorticoid therapy
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
LY3209590
Could I receive a Placebo?
no
Enrollment Goal
264
Trial Dates
July 2020 - September 2021
Trial Phase
2
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-75
Sex
All
Participants must
Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of a Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor) for at least 3 months prior to screening
Participants must have a HbA1c value of 7.0% to 9.5%, inclusive
Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m²), inclusive
Participants must NOT
Participants must not have type 1 diabetes mellitus or latent autoimmune diabetes
Participants must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Participants must not have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)
Participants must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Participants must not have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²
Participants must not have active or untreated cancer
Participants must not be on chronic (>14 days) systemic glucocorticoid therapy
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
LY3209590
Could I receive a Placebo?
no
Enrollment Goal
264
Trial Dates
July 2020 - September 2021
Trial Phase
2
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Adult Type 2 Diabetes Resources
